A meta-analysis performed on 2321 patients with various cancers to confirm that high expression of ANXA2 was correlated with both overall survival (OS) (hazard ratio [HR] 1.56; p < 0.001) and disease-free survival (DFS) (HR 1.47; p < 0.001) 111. Here, ANXA2 is linked to cancer.